Please login to the form below

Not currently logged in


This page shows the latest Cellectis news and features for those working in and with pharma, biotech and healthcare.

Gilead signs $3bn-plus gene-editing deal with Sangamo

Gilead signs $3bn-plus gene-editing deal with Sangamo

The deal with Sangamo means rivals in the CAR-T category such asand off-the-shelf specialist Cellectis won’t be able to use the ZFN technology in their own ... Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’favoured

Latest news

More from news
Approximately 8 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.

  • Pharma deals in May 2015 Pharma deals in May 2015

    Following the collaboration announced in June 2014 with Cellectis, the rumours are now going around that Pfizer may be planning an acquisition with an estimated price tag of $1.6bn.

  • Pharma deals in March 2015 Pharma deals in March 2015

    Also Evaluate reports a cautious approach by big pharma. Novartis, J&J and Pfizer (via a deal with Cellectis) are in the go-kart race but other companies such as Merck

  • Pharma deals during June 2014 Pharma deals during June 2014

    Cellectis has reserved 12 other targets and Pfizer will provide preclinical development assistance for four of these. ... easily. Cellectis plans to open a research site in the US to work more closely with Pfizer.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    350. Medreich/ Meiji Seika. Company acquisition. India-based manufacturing company. 290. Cellectis/ Pfizer.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...